PCM
IMDX

Prelude Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Prelude Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16
Closed -$1K – 2015
2019
Q1 		$1K Buy
+16
New +$1.03K ﹤0.01% 1705

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Prelude Capital Management's IMDX Position: Q2 2019 in Review

Prelude Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2019, closing a stake of 16 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in IMDX in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 54 funds tracked by Wall St. Rank hold IMDX as of Q2 2019.

  • Prelude Capital Management reported no remaining Insight Molecular Diagnostics position as of Q2 2019 after selling out during the quarter.
  • Prelude Capital Management sold 16 Insight Molecular Diagnostics shares in Q2 2019, an estimated $1K.
  • Prelude Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 1 quarter.
  • Prelude Capital Management's Insight Molecular Diagnostics position peaked at $1K in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.